EB 001

Drug Profile

EB 001

Alternative Names: EB-001

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Bonti
  • Class Bacterial proteins; Bacterial toxins
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glabellar lines
  • Phase I Musculoskeletal pain

Most Recent Events

  • 03 May 2017 Interim efficacy data from a phase IIa trial in Glabellar lines released by Bonti
  • 18 Apr 2017 Phase-I clinical trials in Musculoskeletal pain in USA (unspecified route) (Bonti pipeline, April 2017)
  • 18 Apr 2017 Bonti plans a phase II trial for Musculoskeletal pain in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top